Compare Innodata Inc (INOD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Innodata Inc trades at $52.5 (market cap $2.01B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Innodata Inc is far larger — about 2.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 20 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| INOD | MRVI | |
|---|---|---|
Market Cap | $2.01B | $972.90M |
Volume | 722,859 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $121.50 | $9.00 |
52-Week Low | $34.45 | $2.83 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $1.76B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD is trading at $58.38, down 2.55% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 42.71% gross margins and 37.74% ROE, while expanding into motion-capture AI labs and agentic reinforcement learning. Analyst consensus remains positive with 66.7% buy ratings, though valuation metrics appear elevated with a P/E of 45.26.
The outlook balances strong AI services growth against premium valuation concerns. Investment opportunity lies in continued execution on AI data engineering contracts with major tech companies, while risks include customer concentration and competitive pressures in the rapidly evolving AI infrastructure market.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
